""We're gearing up to go into the clinic," Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. "It's going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.""
""Last year, CEO Demis Hassabis said it would have AI-designed drugs in clinical trials by the end of 2025," indicating a shift in the timeline for human studies."
""AlphaFold 2, which uses deep-learning techniques, presented stunning results in 2020, revolutionizing the prediction of protein structures that dictate protein function.""
""In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists' understanding of proteins even further, predicting interactions with DNA and RNA.""
Isomorphic Labs, a biotech spinoff of Google DeepMind, is set to begin human trials for drugs designed by its AI technology, AlphaFold. This follows a delay from the initial timeline set by CEO Demis Hassabis, who had anticipated trials by the end of 2025. AlphaFold has transformed protein structure prediction, which is crucial for drug discovery. The platform's advancements, including AlphaFold 3, allow for the prediction of interactions between proteins and other molecules like DNA and RNA, enhancing scientific understanding and drug development.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]